Genome Sequencing Cost CurveFor most of the history of medicine, doctors have been limited to observing symptoms and trying to alleviate them. This has been especially true for non-infectious diseases stemming from dysfunction in the body, including genetic diseases.With the discovery of DNA structure and function, awarded the 1962 Nobel Prize in Medicine , we started to have a better understanding of how the biological system truly works. PCR technology, awarded the 1993 Nobel Prize in Medicine , would open new ways to analyze it.This further expanded when full genomes started to be sequenced. The first human genome was sequenced in 2003 after 13 years of hard work, for a cost of $3B. Quickly, full-genome sequencing started to become cheaper and cheaper. By 2007, it would cost “only” $1M to sequence a full genome

World's Most Comprehensive Protein Study Highlights Ultima's Commitment to Unlocking the Power of Genomics at ScaleFREMONT, Calif., Jan. 9, 2025 /PRNewswire/ -- Ultima Genomics, Inc., a developer of an ultra-high throughput next-generation sequencing (NGS) platform, today announced that its UG 100™ was selected as the sequencing platform to enable UK Biobank's unprecedented protein study, which will be the world's largest and most comprehensive proteomics study to date. The UG 100™ was selected by a consortium of 14 leading biopharma companies funding the UK Biobank Pharma Proteomics Project and will be used in conjunction with Thermo Fisher Scientific's Olink® Explore HT proteomics platform to play a central role in this first-of-its-kind effort in understanding disease progression and advancing personalized medicine. This unparalleled project aspires to quantify more than 5,400 protein markers across 600,000 samples, including those from half a million UK Biobank participants and 100,000 second samples taken from a subset of these participants across different time points (spanning up to 15 years). This will allow researchers to explore a unique and unprecedented database. The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence disease progression and overall health

Myriad Genetics has announced a collaboration with Ultima Genomics to evaluate the potential of the UG 100 sequencing platform and ppmSeq technology in advancing clinical tests in oncology and reproductive genomics.